

Technology Opportunity, Ref. No. IS-14/0092

Minimally invasive targeted delivery of drugs / genes / biologicals

This novel electro-spray device allows for subtle localized and targeted delivery of bioactive compounds either through natural body openings or by minimally invasive surgery. It has been successfully shown that tumor volume in a mouse-model was substantially reduced upon treatment with known chemotherapeutics. In another, ex-vivo experiment, highly efficient gene transfection was achieved, which holds potential for drug delivery and gene therapy to solid organs.

Keywords Electro spray, targeted drug delivery, targeted gene delivery, endoscopic delivery

Inventors S. Boehringer, A. Gazdhar, T. Geiser, D. Hradetzky, E. Schkommodau,

Background The targeted delivery of bioactive compounds locally to diseased organ and also at difficult to access regions of the human body is of great medical interest. Gene therapy approaches, currently hindered due to adverse effects associated with viral vectors, and chemotherapies, accompanied with severe side effects due to systemic administration, will greatly benefit from an efficient targeted in-situ delivery method. The inventive device has potential for cost-effective and less invasive therapy of various cancer types and to improve/prolong life in currently incurable diseases like pulmonary fibrosis.

Invention The single-port electro spray device for targeted, local treatment for intraluminal tumors or difficult to access regions can be applied using endoscopic or catheter application. With a tunable electric field, the device nebulizes and accelerates droplets containing the therapeutic agent in a controlled manner towards the target region. By choosing the optimal parameters, efficient and local penetration of otherwise poorly permeating chemical compounds or biologicals into living cells is achieved.



Lung tumors sub-cutaneously grown in mice.

Left: Untreated control, right: After two treatments with Cisplatin electro spray

Application Tumor targeting incl. intraluminal tumors, non-viral gene therapy to solid organs.

Patent Status US Patent 9,731,306 granted, EP2892595 accepted for grant

Contact *Unitectra, Technology Transfer University Bern, Dr. Martin Binggeli,
Hochschulstrasse 6, CH-3012 Bern, +41 (0)31 631 3231, mail@unitectra.ch*